Evaluation of P wave Dispersion and Tissue Doppler Imaging for Predicting Paroxysmal Atrial Fibrillation in Patients with Hypertension
Keywords:Hypertension, Atrial fibrillation, Tissue Doppler echocardiography, Tissue Doppler imaging, Electromechanical delay
Background: There are no previous studies dealing with paroxysmal atrial fibrillation (AF) and hypertension using electrocardiogram and tissue doppler imaging (TDI). The aim of this study was to investigate and identify the predictive indicators for paroxysmal AF in hypertensive patients using
P wave dispersion (Pd) and TDI.
Methods: Patients with hypertension were enrolled. Patients with paroxysmal AF were classified as the PAF group, and patients without a history of paroxysmal AF were classified as the NAF group. The clinical data, P wave indicators and TDI indicators were collected and compared between the two groups.
Results: A total of 120 patients were enrolled into the study with 40 cases in the PAF group and 80 cases in the NAF group. Compared with NAF group, Pd, maximum P wave duration (Pmax), left ventricular end-diastolic dimension (LVEDd) and left atrial dimension (LAD) were significantly longer (P < .05) in the PAF group. PAL, PAI, PAR, LR, LI and IR were significantly longer (P < .05) in the PAF group than in the NAF group. As for ROC analysis, Pd and PAL had the greatest area under the curve. The best diagnostic value of Pd and PAL was 40ms and 78ms, respectively. The combination of Pd ≥40ms with Pmax ≥ 110ms showed higher specificity and positive predictive value but decreased sensitivity and negative predictive value for paroxysmal AF.
Conclusions: The PAF group had significantly longer atrial electromechanical time and higher Pd compared with NAF group. The combination of Pd and TDI may be helpful to predict the onset of paroxysmal AF in patients
Andrade J, Khairy P, Dobrev D, Nattel S. 2014. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 114:1453-1468.
Andrikopoulos GK, Dilaveris PE, Richter DJ, et al. 2000. Increased variance of P wave duration on the electrocardiogram distinguishes patients with idiopathic paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 23:1127-1132.
Association EHR, Fuster V, Rydén LE, et al. 2007. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Commi. Eur Heart J 59:1231-1265.
Buxton AE, Josephson ME. 1981. The role of P wave duration as a predictor of postoperative atrial arrhythmias. Chest 80:68-73.
Chugh SS, Havmoeller R, Narayanan K, et al. 2014. Worldwide Epidemiology of Atrial Fibrillation A Global Burden of Disease 2010 Study. Circulation 129:837-847.
Ciaroni S, Cuenoud L, Bloch A. 2000. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J 139:814-819.
de Vos CB, Pisters R, Nieuwlaat R, et al. 2010. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 55:725-731.
Dilaveris PE, Gialafos EJ, Sideris SK, et al. 1998. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 135:733-738.
Dilaveris PE, Gialafos EJ, Andrikopoulos GK, et al. 2000. Clinical and Electrocardiographic Predictors of Recurrent Atrial Fibrillation. Pacing Clin Electrophysiol 23:352-358.
Guo JH. 1999. P wave dispersion. J Clin Electrocardiol 189-192.
Guo YP. Fang WH, Cheng S-T. 2007. Analyzing effects of P wave dispersion on paroxysmal atrial fibrillation. Chin J Prim Med Pharm 14:411-412.
Healey JS, Connolly SJ. 2003. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. American Journal of Cardiology 91:9-14.
Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. 2013. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 34:1475-1480.
Huxley RR. 2011. Absolute and Attributable Risks of Atrial Fibrillation in Relation to Optimal and Borderline Risk Factors The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 123:1501-1508.
Khaji A, Kowey PR. 2017. Update on atrial fibrillation. Trends Cardiovasc Med 27:14-25.
Li D, Shinagawa K, Pang L, et al. 2001. Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing induced Congestive Heart Failure. Circulation 104:2608-2614.
Mori K, Hayabuchi Y, Inoue M, et al. 2007. Myocardial strain imaging for early detection of cardiac involvement in patients with Duchenne’s progressive muscular dystrophy. Echocardiography 24:598-608.
Ozer N, Aytemir K, Atalar E, et al. 2000. P wave dispersion in hypertensive patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 23:1859-1862.
Piccini JP, Fauchier L. 2016. Rhythm control in atrial fibrillation. The Lancet 388:829-840.
Pieruzzi F, Antolini L, Salerno FR, et al. 2015. The role of blood pressure, body weight and fat distribution on left ventricular mass, diastolic function and cardiac geometry in children. J Hypertens 33:1182-1192.
Rein A, O’Donnell C, Colan S, Sear-Brent L, Marx G. editors. 2000. Right and left atrial contraction time and electromechanical coupling using tissue velocity imaging. Circulation 383.
Rein AJ, O’Donnell CP, Colan SD, Marx GR. 2003. Tissue velocity Doppler assessment of atrial and ventricular electromechanical coupling and atrioventricular time intervals in normal subjects. Am J Cardiol 92:1347-1350.
Schneider MP, Hua TA, Böhm M, et al. 2010. Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition : A Meta-Analysis. J Am Coll Cardiol 55:2299-2307.
Takahashi S, Katayama K, Watanabe M, et al. 2016. Preoperative Tissue Doppler Imaging-Derived Atrial Conduction Time Predicts Postoperative Atrial Fibrillation in Patients Undergoing Mitral Valve Surgery for Mitral Valve Regurgitation. Circ J 80:101-109.
Tenekecioglu E, Karabulut A, Yilmaz M. 2010. Comparison of tissue Doppler dynamics with Doppler flow in evaluating left atrial appendage function by transesophageal echocardiography in prehypertensive and hypertensive patients. Echocardiography 27:677-686.
Tong D. 2013. The relation between P wave dispersion and primary hypertension complicated with paroxysmal atrial fibrillation. Prevention and Treatment of Cardio-Cerebral-Vascular Disease 13:376-378.
Wang CQ, Zhou M, Zhan ZQ, et al. 2005. Predictive value of P wave dispersion on paroxysmal atrial fibrillation in primary hypertensive patients. Clinical Focus 245-7.
Yuan YQ, Liu HL, Ma YX. 2003. The effect of the inhibitors of angiotensin converting enzyme on P wave dispersion in patients with organic heart disease and paroxysmal atrial fibrillation. J Clin Cardiol 690-691.
Zhang H, Xin-Zheng LU. 2012. Hypertension and Atrial Fibrillation:Diagnostic Approach,Prevention and Treatment. Position Paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. Adv Cardiovasc Dis 30:239-252.
Zhou ZQ, Hu DY, Chen J, et al. 2004. [An epidemiological survey of atrial fibrillation in China]. Zhonghua Nei Ke Za Zhi 43:491-494.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).